An unresolved question is whether loss of expression of p16INK4a (the protein product of the CDKN2A gene which functions as a negative regulator of cyclin-dependent kinase activity—hereafter p16) by immunohistochemistry can identify likely CDKN2A-inactivated meningiomas to be selectively confirmed by follow-up molecular testing. Here, CDKN2A is linked to meningioma.